Chris Schott
Stock Analyst at JP Morgan
(4.09)
# 509
Out of 5,078 analysts
149
Total ratings
66.99%
Success rate
7.15%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Overweight | $1,050 → $1,150 | $1,057.89 | +8.71% | 23 | Nov 18, 2025 | |
| OGN Organon & Co. | Maintains: Underweight | $14 → $12 | $7.60 | +57.89% | 3 | Nov 11, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $26 → $28 | $26.72 | +4.79% | 19 | Nov 6, 2025 | |
| PRGO Perrigo Company | Downgrades: Neutral | $32 → $20 | $13.85 | +44.40% | 13 | Nov 6, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $230 → $200 | $127.25 | +57.17% | 3 | Nov 5, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $675 → $775 | $728.97 | +6.31% | 9 | Nov 4, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $250 → $260 | $225.11 | +15.50% | 4 | Nov 3, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $145 → $150 | $124.33 | +20.65% | 8 | Oct 31, 2025 | |
| ELAN Elanco Animal Health | Upgrades: Overweight | $18 → $24 | $22.62 | +6.10% | 4 | Oct 7, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $12 → $14 | $12.31 | +13.73% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $950 → $800 | $750.11 | +6.65% | 8 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $185 → $175 | $177.78 | -1.56% | 4 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $39.90 | +5.26% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $337.49 | -20.00% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $25.27 | +34.55% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $101.83 | +22.75% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $10.70 | +30.84% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.27 | +766.14% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.05 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $49.18 | +58.60% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $1.33 | +71,328.57% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.52 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $23.70 | +110.97% | 3 | Nov 2, 2018 |
Eli Lilly and Company
Nov 18, 2025
Maintains: Overweight
Price Target: $1,050 → $1,150
Current: $1,057.89
Upside: +8.71%
Organon & Co.
Nov 11, 2025
Maintains: Underweight
Price Target: $14 → $12
Current: $7.60
Upside: +57.89%
Teva Pharmaceutical Industries
Nov 6, 2025
Maintains: Overweight
Price Target: $26 → $28
Current: $26.72
Upside: +4.79%
Perrigo Company
Nov 6, 2025
Downgrades: Neutral
Price Target: $32 → $20
Current: $13.85
Upside: +44.40%
Zoetis
Nov 5, 2025
Maintains: Overweight
Price Target: $230 → $200
Current: $127.25
Upside: +57.17%
IDEXX Laboratories
Nov 4, 2025
Maintains: Overweight
Price Target: $675 → $775
Current: $728.97
Upside: +6.31%
AbbVie
Nov 3, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $225.11
Upside: +15.50%
Gilead Sciences
Oct 31, 2025
Maintains: Overweight
Price Target: $145 → $150
Current: $124.33
Upside: +20.65%
Elanco Animal Health
Oct 7, 2025
Upgrades: Overweight
Price Target: $18 → $24
Current: $22.62
Upside: +6.10%
Amneal Pharmaceuticals
Sep 16, 2025
Maintains: Overweight
Price Target: $12 → $14
Current: $12.31
Upside: +13.73%
Jun 9, 2025
Maintains: Overweight
Price Target: $950 → $800
Current: $750.11
Upside: +6.65%
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $177.78
Upside: -1.56%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $39.90
Upside: +5.26%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $337.49
Upside: -20.00%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $25.27
Upside: +34.55%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $101.83
Upside: +22.75%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $10.70
Upside: +30.84%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.27
Upside: +766.14%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $7.05
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $49.18
Upside: +58.60%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $1.33
Upside: +71,328.57%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.52
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $23.70
Upside: +110.97%